FRANCISCO DE PAULA
TELLEZ PEREZ
Profesor asociado de Ciencias de la Salud
Hospital Universitario Virgen del Rocío
Sevilla, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Universitario Virgen del Rocío (28)
2024
2021
-
Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy
Journal of Hepatology, Vol. 74, Núm. 4, pp. 801-810
-
Progression to hepatitis C virus micro-elimination in people living with HIV in Spain
Clinical Microbiology and Infection
2019
-
DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients
Medicine (United States), Vol. 98, Núm. 32
-
High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world
Journal of Hepatology, Vol. 71, Núm. 5, pp. 876-888
-
Parenteral drug use as the main barrier to hepatitis C treatment uptake in HIV-infected patients
HIV Medicine, Vol. 20, Núm. 6, pp. 359-367
-
Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort
PLoS ONE, Vol. 14, Núm. 8
-
The simplification of the diagnosis process of chronic hepatitis C is cost-effective strategy
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 10, pp. 634-641
2018
2017
-
Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 3, pp. 487-494
2016
-
Effectiveness of ritonavir-boosted protease inhibitor monotherapy in clinical practice even with previous virological failures to protease inhibitor-based regimens
PLoS ONE, Vol. 11, Núm. 2
-
Hepatic safety of rilpivirine/emtricitabine/tenofovir disoproxil fumarate fixed-dose single-tablet regimen in HIV-infected patients with active hepatitis C virus infection: The hepatic study
PLoS ONE, Vol. 11, Núm. 5
-
No evidence of firstly acquired acute hepatitis C virus infection outbreak among HIV-infected patients from Southern Spain: A multicentric retrospective study from 2000-2014
BMC Infectious Diseases, Vol. 16, Núm. 1
2015
-
Dimension of chronic hepatitis C virus in HIV-infected patients in the interferon-free era: an overview from south Spain
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 11, pp. 2247-2255
-
Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 9, pp. 1879-1884
-
Low efficacy of pegylated interferon plus ribavirin plus nitazoxanide for HCV genotype 4 and HIV coinfection
PLoS ONE, Vol. 10, Núm. 12
-
Low risk of liver decompensation among human immunodeficiency virus/hepatitis C virus-coinfected patients with mild fibrosis in the short term
Hepatology, Vol. 61, Núm. 5, pp. 1503-1511
2014
-
A 24-week treatment strategy with pegylated interferon/ribavirin in HIV/hepatitis C virus genotype 3-coinfected patients who achieved a rapid virologic response results in a high sustained virologic response rate
Clinical Infectious Diseases, Vol. 58, Núm. 1, pp. 130-133
-
Clinical and virological efficacy of etravirine plus two active nucleos(t)ide analogs in an heterogeneous HIV-infected population
PLoS ONE, Vol. 9, Núm. 5
-
Predictors of early mortality in very elderly patients with bacteremia: A prospective multicenter cohort
International Journal of Infectious Diseases, Vol. 26, pp. 83-87